ASCO GU 2023: Rucaparib or Physician’s Choice in Metastatic Castration-Resistant Prostate Cancer
Posted: 03/06/2023 | By: Melissa E. Fryman, MS

The phase III TRITON3 trial investigated rucaparib vs physician-selected single-agent therapy in patients with metastatic castration-resistant prostate cancer and certain genetic alterations in terms of progression-free survival. These findings were published by Fizazi et al in The New England Journal of Medicine and also presented at the 2023 ASCO Genitourinary Cancers Symposium.

Question 1 of 5

Patients enrolled in the TRITON3 study had metastatic castration-resistant prostate cancer with mutations in which of the following genes?

Choose 1